WELLESLEY HILLS, Mass.--(BUSINESS WIRE)--Point Therapeutics, Inc. (NASDAQ: POTP) today announced that it has received proxies sufficient to approve the pending merger transaction with DARA BioSciences, Inc. and certain matters related thereto, including a reverse stock split. Point’s adjourned annual stockholders’ meeting will reconvene at 10:00 am on February 12, 2008 at the law offices of Ropes & Gray LLP, One International Place, 36th Floor, Boston, MA 02110, at which time Point expects to finalize stockholder approval of the DARA merger. Point encourages all of its stockholders who have not yet submitted proxies to vote at the annual meeting. Point’s Board of Directors has determined that the merger with DARA Biosciences is advisable and fair to and in the best interests of Point stockholders and recommends that Point stockholders vote “FOR” all the proposals.
